Relationship between serum SREBP-1, SAP and endocrine metabolism in patients with polycystic ovary syndrome
10.3760/cma.j.cn.115807-20200506-00147
- VernacularTitle:多囊卵巢综合征患者血清SREBP-1、SAP与内分泌代谢的关系研究
- Author:
Wenxuan XU
1
;
Lifang YOU
Author Information
1. 杭州市余杭区第一人民医院妇科 311100
- Keywords:
Polycystic ovary syndrome;
Serum sterol regulatory element binding protein-1;
Serum amyloid P;
Endocrine metabolism
- From:
Chinese Journal of Endocrine Surgery
2021;15(4):438-441
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between serum sterol regulatory element binding protein-1 (SREBP-1) , serum amyloid P (SAP) and endocrine metabolism in patients with polycystic ovary syndrome.Methods:75 patients with polycystic ovary syndrome (study group) and 70 healthy women (control group) admitted to the First People’s Hospital of Yuhang District from Mar. 2018 to Feb. 2020 were enrolled. Various indexes were detected in both groups, including body mass index (BMI) , SREBP-1, SAP, triglyceride (TG) , total cholesterol (TC) , high-density lipoprotein (HDL-C) , and low-density lipoprotein (LDL-C) , fasting blood glucose (FBG) , fasting insulin (FINS) , and insulin resistance index (HOMA-IR) . The study group was further divided into two subgroups according to BMI, overweight group and normal group. SREBP-1 and SAP were compared between the two groups. Pearson correlation analysis was used to analyze the correlation between SREBP-1, SAP, blood lipid index, blood glucose index and BMI in patients with polycystic ovary syndrome.Results:The body weight and BMI index of study group were higher than those of control group [ (72.23±4.84) kg vs (58.23±3.25) kg, (25.02±2.75) kg/m 2 vs (22.11±1.34) kg/m 2, P<0.05]. The levels of serum SREBP-1 and SAP in the study group were significantly higher than those in the control group [ (334.78±32.06) pg/ml vs (206.34±25.71) pg/ml, (206.34±25.71) mg/U vs (39.16 ±0.58) mg/U, P<0.05]. The expression levels of TG, TC, LDL-C, FBG, FINS, and HOMA-IR in the study group were higher than those in the control group [ (2.32±0.71) vs (1.53±0.52) , (4.85±0.54) vs (3.41±0.66) , (3.06±0.75) vs (2.11±0.89) , (6.45±0.62) vs (5.59±0.76) , (16.14±1.03) vs (13.02±1.34) , (1.67±0.38) vs (1.18± 0.26) , P<0.05]; HDL-C expression level in the study group was lower than that in the control group [ (1.43±0.56) vs (1.71±0.42) , P<0.05]. The levels of SREBP-1 and SAP in overweight group were higher than those in normal group [ (339.19±27.63) pg/ml vs (281.67±20.18) pg/ml, (53.26±0.59) mg/U vs (42.48±0.67) mg/U, P<0.05]. Serum SREBP-1 and SAP in the study group were positively correlated with TG, TC, LDL-C, HOMA-IR, and BMI, and were negatively correlated with HDL-C ( P<0.05) . Conclusion:SREBP-1 and SAP levels are elevated in patients with polycystic ovary syndrome, which are significantly correlated with TG, TC, LDL-C, HOMA-IR, BMI, and HDL-C, and can cause endocrine disorder by affecting glucose and lipid metabolism.
